CRISPR And Cas Genes Market Size, Share & Trends Analysis Report By Product & Service, By Application (Biomedical, Agricultural), By End-use (Biotechnology & Pharmaceutical Companies), By Region, And Segment Forecasts, 2023 - 2030

CRISPR And Cas Genes Market Trends

The global CRISPR and Cas genes market size was valued at USD 2.57 billion in 2022 and is expected to grow at a compound annual growth rate (CAGR) of 17.15% from 2023 to 2030. Recent advancements in biotechnological research have enabled CRISPR & Cas gene systems to find widespread applications that directly or indirectly aid human health. For example, somatic gene editing that involves engineering an individual’s DNA, have been used to treat diseases like HIV, sickle-cell disease and transthyretin amyloidosis. The technique is anticipated to be part of novel therapeutic options for different types of cancers. The technological advancements in CRISPR & Cas gene system have contemporarily revolutionized the area of cancer research and therapeutics.

Moreover, the COVID-19 pandemic has boosted the usage of CRISPR & Cas gene technology and has been widely used in nucleic acid detection due to its reliability and sensitivity. Since the advent of CRISPR as a tool for DNA editing, it is increasingly being adopted by key biotechnology and pharmaceutical companies for the development of drugs and therapies. For instance, in August 2022, iNtRON Biotechnology announced that they are developing a customized CRISPR/Cas system for the genetic modification of bacteria and bacteriophages.

The CRISPR technology improves the therapeutic efficacy of modified T-cells for the treatment of various malignancies. Additionally, the development of chimeric antigen receptor T (CAR-T) cells is strongly related to cancer treatment. In May 2022, Caribou Biosciences, Inc. presented data on the mechanism underlying the potential of chRDNA genome-editing technology in primary human T cells. It provides a reproducible and robust technique to boost the specificity of genome editing, and it improves the efficacy of allogeneic cell therapies. These developments are anticipated to drive the growth of the market in the coming years.

Innovative technologies such as karyotyping, neonatal screening, viral screening and others have boosted the demand for gene editing techniques like CRISPR & CRISPR-Associated (Cas) gene technology. Moreover, the use of CRISPR & Cas gene technology to enhance agricultural produce by innovative breeding strategies has increased the adoption of these technologies in the biotechnology industry. Increased environmental, and pest resistance, improved shelf life are some of the potential application of this technology that is anticipated to boost the market growth in near future.

Product & Service Insights

The product segment dominated the market in 2022 and accounted for the highest share of 78.86%. Several cutting-edge technologies, such as CRISPR gene editing kits, have been developed to meet the growing demands for genome editing solutions. The increased market share is due to the availability of enhanced individual products that can be used to achieve a variety of goals, including simple gene knockouts, selective genome cleavage, reduced off-target cutting, genome engineering, and higher specificity.

The service segment is expected to grow at the fastest CAGR of 18.49% by 2030. Increased investments in gene editing-based R&D along with the introduction of several applications are anticipated to drive the growth of the service segment over the forecast period. For instance, in July 2022, UK charity (The British Heart Foundation) provided USD 36 million to an international team to develop innovative gene-editing treatments for inherited heart diseases. Recent gene editing techniques, particularly the CRISPR technology, has offered several opportunities to combat cardiovascular disease.

Application Insights

The biomedical applications segment dominated the market in 2022 and accounted for 92.27% of the total revenue share. The increasing utilization CRISPR gene-editing technologies in a number of biological sciences fields has significantly boosted this segment's higher revenue. The effectiveness and specificity of this technology has been enhanced by better delivery methods and the introduction of nanocarriers. The number of studies and publications that used this method to modify the genomes of human somatic cells and induced pluripotent stem cells has been significantly increased. Additionally, there are companies that provide commercial kits and services to help researchers who are working in this domain.

The agricultural segment is anticipated to register the fastest CAGR of 21.13% over the forecast period. Improvement in agricultural production through incorporation of innovative breeding technology has increased the access to nutrition-rich foods globally. For instance, in June 2019, researchers at the Cold Spring Harbor Laboratory implemented CRISPR/Cas9 technology to induce mutations in the flowering suppressor of tomato, which resulted in rapid flowering and improved compact growth of tomatoes, finally an early yield.

End-use Insights

The biotechnology and pharmaceutical companies dominated the market in 2022, accounting for 49.68% of overall revenue share. It is also the fastest growing segment over the forecast period as pharmaceutical companies are utilizing these technologies to quickly identify and validate new therapeutic targets and to produce better biological models for human diseases in less time. The market is also anticipated to be further driven by the rising number of biotechnology companies using gene modification for both research and commercial purposes.

Additionally, there is a huge demand for CRISPR-based gene-editing methods for the creation of innovative medicines as cell and gene therapies. CRISPR's core architecture has been modified by extending its reach into the epigenome and granting control over epigenetic inheritance. For instance, in April 2021 researchers from the Massachusetts Institute of Technology and the University of California created a CRISPR on-off switch to regulate gene expression.

Regional Insights

North America dominated the market and accounted for the highest revenue share of 38.37% in 2022. The growing biopharmaceutical R&D as well as the involvement of several pharmaceutical corporations in the creation of novel therapeutics has contributed towards the region’s growth. For instance, in May 2020, Merck KGaA received U.S. approval. For two of its CRISPR Cas9-driven gene-editing patents.

Asia Pacific region is anticipated to witness the fastest CAGR of 17.53% during the forecast period. The increasing government investment in R&D to develop novel treatments is aiding in market expansion Japan and China is anticipated to support the region’s growth. For instance, in March 2021, Japanese biotech company Setsuro Tech received a patent for CRISPR-Cas9 technology from Dublin-based ERS Genomics. The company is creating animal and cell models using these advanced technologies. Such initiatives are predicted to enhance CRISPR technology adoption in the region, further contributing towards revenue generation.

CRISPR And Cas Genes Market Share Insights

Several strategic initiatives, product developments, and regional expansions are key strategies that could contribute in market development. For instance, in February 2023, Ensoma completed the acquisition of Twelve Bio ApS, a company exploring therapeutic applications of next-generation CRISPR-Cas medicines. Such initiatives are expected to boost the market growth in the coming years. Some of the key players in the CRISPR And Cas Genes market include:

• AstraZeneca plc.

• Addgene

• Caribou Biosciences, Inc.

• Cellectis

• CRISPR Therapeutics

• Editas Medicine, Inc.

• eGenesis

• F. Hoffmann-La Roche Ltd.

• Horizon Discovery Group plc

• GenScript

• Danaher

• Intellia Therapeutics, Inc.

• Lonza

• Merck KGaA

• Takara Bio Inc.

• Thermo Fisher Scientific, Inc.

• Synthego

• Mammoth Biosciences

• Inscripta, Inc.

• Cibus

• Beam Therapeutics

• PLANTeDIT

• Vertex Pharmaceuticals Incorporated

• Hera BioLabs

• OriGene Technologies, Inc.

• Recombinetics, Inc.

CRISPR And Cas Genes Market Report Scope

Global CRISPR And Cas Genes Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For the purpose of this report, Grand View Research has segmented the CRISPR and Cas genes market on the basis of product & service, application, end-use, and region

• Product & Service Outlook (Revenue, USD Million, 2018 - 2030)

  • By Product

    • Kits & Enzymes

      • Vector-based Cas

      • DNA-free Cas

    • Libraries

    • Design Tool

    • Antibodies

    • Others

  • By Service

    • Cell Line Engineering

    • gRNA Design

    • Microbial Gene Editing

    • DNA Synthesis

• Application Outlook (Revenue, USD Million, 2018 - 2030)

  • Biomedical

    • Genome Engineering

    • Disease Model Studies

    • Functional Genomics

    • Epigenetics

    • Others

  • Agricultural

• End-use Outlook (Revenue, USD Million, 2018 - 2030)

  • Biotechnology & Pharmaceutical Companies

  • Academics & Government Research Institutes

  • Contract Research Organizations (CROs)

• Regional Outlook (Revenue, USD Million, 2018 - 2030)

  • North America

    • U.S.

    • Canada

  • Europe

    • Germany

    • France

    • Italy

    • Spain

    • U.K.

    • Denmark

    • Sweden

    • Norway

  • Asia Pacific

    • China

    • Japan

    • India

    • South Korea

    • Thailand

    • Australia

  • Latin America

    • Brazil

    • Mexico

    • Argentina

  • Middle East & Africa

    • South Africa

    • Saudi Arabia

    • UAE

    • Kuwait